| Name | Title | Contact Details |
|---|
With operation centers in the United States and the United Kingdom and an R&D center of excellence in Finland, CRF Health is committed to driving the global change to higher-quality outcomes and more efficient paper-free clinical trials through improved patient engagement via intuitive and patient-focused eCOA (electronic Clinical Outcome Assessment) technology. By improving the process of conducting clinical studies, we help companies bring new medicines to market quickly, safely and more cost-effectively.
Allegiance Life is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Block Imaging International is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lansing, MI. To find more information about Block Imaging International, please visit www.blockimaging.com
Heritage Health Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.